MK-4464 + Pembrolizumab + 89Zr-MK-4464
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors
Conditions
Advanced/Metastatic Solid Tumors, Neoplasms
Trial Timeline
Sep 25, 2022 → Sep 18, 2025
NCT ID
NCT05514444About MK-4464 + Pembrolizumab + 89Zr-MK-4464
MK-4464 + Pembrolizumab + 89Zr-MK-4464 is a phase 1 stage product being developed by Merck for Advanced/Metastatic Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT05514444. Target conditions include Advanced/Metastatic Solid Tumors, Neoplasms.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Solid Tumors were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05514444 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors